Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...